There are currently 25 active clinical trials seeking participants for Healthy Participants research studies. The states with the highest number of trials for Healthy Participants participants are California, Florida, Texas and Kansas.
Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg
NCT06348303
Recruiting
Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/05/2024
Locations: ClinOhio Research Institute, Columbus, Ohio
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
NCT06713590
Recruiting
This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/27/2025
Locations: Celerion, Inc, Tempe, Arizona
Conditions: Healthy Participants
Register for Updates
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
NCT06745271
Recruiting
The primary purpose of this study is to determine the routes, rates of elimination, mass balance of total radioactivity and metabolite profiles following a single oral dose of \[14C\]-tebapivat. To characterize the PK of tebapivat and \[13C2,15N3\]-tebapivat and determine the absolute bioavailability following single oral dose of \[14C\]-tebapivat relative to single intravenous microdose of \[13C2,15N3\]-tebapivat to healthy male participants.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
01/24/2025
Locations: Taha El-Shahat, Madison, Wisconsin
Conditions: Healthy Participants
Register for Updates
A Study of LY4060874 in Healthy Participants
NCT06709820
Recruiting
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 16 study visits.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Fortrea, Inc., Dallas, Texas +1 locations
Conditions: Healthy Participants
Register for Updates
A Study of STAR-0310 in Healthy Adult Participants
NCT06782477
Recruiting
This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants. There are 4 planned cohorts and potentially up to 1 additional cohort which may comprise of healthy adult participants of Japanese descent.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/15/2025
Locations: Austin Clinical Research Unit - Early Clinical Development, Austin, Texas
Conditions: Healthy Participants
Register for Updates
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
NCT06502379
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/13/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
Register for Updates
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
NCT06491550
Recruiting
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/10/2025
Locations: Research Site, Glendale, California +1 locations
Conditions: Healthy Participants
Register for Updates
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
NCT05644977
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
01/09/2025
Locations: Cypress, California, Cypress, California +10 locations
Conditions: Healthy Participants, Alzheimer's Disease Dementia
Register for Updates
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
NCT06417229
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
01/08/2025
Locations: ICON Lenexa, Lenexa, Kansas
Conditions: Healthy Participants
Register for Updates
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
NCT06138795
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/20/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants
NCT06716879
Recruiting
The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic parameters of 2 dose strengths of donzakimig, each administered subcutaneously as a single dose, in healthy Chinese and Japanese study participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/20/2024
Locations: UP0142 1, Anaheim, California
Conditions: Healthy Participants
Register for Updates
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
NCT06568458
Recruiting
The Purpose of the Study is to Assess the Drug Interaction and Bioavailability of BMS-986278 in Tablet Formulations and the Effect that Food has on BMS-986278 in Tablet Formulation in Healthy Participants
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/16/2024
Locations: Local Institution - 0002, Lenexa, Kansas +1 locations
Conditions: Healthy Participants
Register for Updates